Zoran Andric

Statistics

Publications

Citations

117

H-Index

Active since

2013

Affiliations

University Hospital Medical Center Bezanijska kosa(Current)

Zoran Andric is an author at University Hospital Medical Center Bezanijska kosa specializing in lung cancer pharmacotherapy, oncology, and oncology pharmacotherapy.

Publications per year

2013–2024

Publications

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

Martin Reck, Rafał Dziadziuszko, Shunichi Sugawara et al. · Lung Cancer · 2024 · 67 citations

Medicine, Oncology, Pharmacology +10

A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).

Suresh S. Ramalingam, Glenwood Goss, Zoran Andric et al. · Journal of Clinical Oncology · 2013 · 28 citations

Pharmacy, Oncology, Pharmacotherapy +10

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

Konstantinos Syrigos, Istvan Abert, Zoran Andric et al. · BioDrugs · 2021 · 22 citations · Full text

Pharmacy, Oncology, Pharmacology +13

1–3 of 3